Doctor Jieling Chen

Doctor Jieling Chen

AstraZeneca BioPharmaceuticals, Gaithersburg (United States of America)

Member of:

Jieling Chen is a health economist and outcomes researcher with 20 years of experience in health care industry. Expertise includes real-world evidence generation, health service research, economic modeling, and outcomes research. She has extensive experience in diabetes, cardiovascular disease, and vaccine areas. Outside of work, Jieling enjoys reading non-fiction books and listening to podcasts, especially those on improving healthspan. Easy hikes, Pilates, and eating out with friends are her favorite activities.

Presentations

A pooled health-economic analysis of DAPA-HF and DELIVER: A French cost-effectiveness analysis of dapagliflozin for the treatment of patients with heart failure

Event: Heart Failure 2023

Topic: Treatment

Session: Chronic heart failure - treatment 4

Access

Quality of life (QoL) in patients with heart failure with preserved ejection fraction (HFpEF): a systematic review

Event: ESC Congress 2022

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Chronic heart failure - HFpEF - HFrEF - HFmREF

Access

Effects of pre-existing heart failure with preserved ejection fraction (HFpEF) on the outcomes of patients with COVID-19: a systematic review

Event: Heart Failure 2022

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Basic & Translational Late-Breaking Science

Access

Doctor Jieling Chen

Biography

Contributor content

A pooled health-economic analysis of DAPA-HF and DELIVER: A French cost-effectiveness analysis of dapagliflozin for the treatment of patients with heart failure

Quality of life (QoL) in patients with heart failure with preserved ejection fraction (HFpEF): a systematic review

Effects of pre-existing heart failure with preserved ejection fraction (HFpEF) on the outcomes of patients with COVID-19: a systematic review

ESC 365 is supported by